Natco Pharma receives FDA approval for Everolimus tablets, launching generic version of Afinitor Disperz in U.S. market.

NATCO Pharma said that it has received approval of its ANDA for Everolimus tablets for oral suspension (TFOS), a generic version of AFINITOR DISPERZ by Novartis Pharmaceutical Corporation.

Natco Pharma has received US FDA approval for its generic version of Everolimus tablets for oral suspension, indicated for ...

The approval is for the Abbreviated New Drug Application (ANDA) for Everolimus tablets for oral suspension (TFOS) of ...

Natco Pharma announced approval of its ANDA for Everolimus tablets for oral suspension (TFOS), 2mg, 3mg and 5mg, a generic version of AFINITOR DISPERZ by Novartis Pharmaceutical Corporation. NATCO's ...

Breckenridge Pharmaceutical, Inc., -the U.S. subsidiary of Towa International that markets, distributes, and sells generic pharmaceuticals in the United States, - announced today that the Food and ...

Multiple Sclerosis Therapeutics Market is estimated to be valued at USD 30.12 Bn in 2024 and is expected to reach USD 39.55 Bn by 2031, exhibiting a CAGR of 4%. BURLINGAME, CA, UNITED STATES ...

Multiple Sclerosis Therapeutics Market is estimated to be valued at USD 30.12 Bn in 2024 and is expected to reach USD 39.55 Bn by 2031, exhibiting a CAGR of 4% ...

Rapcabtagene autoleucel is under clinical development by Novartis and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis ...

Tractor Supply's nearly $15 billion annual revenue and its current value on the stock market rank the business among the largest public companies headquartered in the Nashville area. The company ...